Press release
HR+ HER2-ve Breast Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers
Explore our latest breakthroughs in HR+ HER2-ve Breast Cancer Research. Learn more about our innovative pipeline today! @ HR+ HER2-ve Breast Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the HR+ HER2-ve Breast Cancer Pipeline Report
* In November 2024:- Tolmar Inc.- Phase 3,Single Arm,Open-Label Study Evaluating Ovarian Suppression Following 3 Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination With Endocrine Therapy in Premenopausal Subjects With Hormone-Receptor-Positive (HR+),Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer.
* In October 2024:- Novartis Pharmaceuticals- The purpose of this Cohort Treatment Plan is to allow access to alpelisib for patients diagnosed with HR-positive, HER2-negative advanced breast cancer with mutated phosphoinositide 3-kinase who progressed on or after AI treatment. The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.
* DelveInsight's HR+ HER2-ve Breast Cancer pipeline report depicts a robust space with 50+ active players working to develop 53+ pipeline therapies for HR+ HER2-ve Breast Cancer treatment.
* The leading HR+ HER2-ve Breast Cancer Companies such as Regor Therapeutics, Seagen Inc., CytomX Therapeutics, Taizhou EOC Pharma, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Daiichi Sankyo, Inc., Tyme, Inc., Context Therapeutics, Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Simcere Pharmaceutical Co., Kind Pharmaceuticals, Merus N.V., Atossa Therapeutics, Roche and others.
* Promising HR+ HER2-ve Breast Cancer Therapies such as TQB3616 capsule, NTQ1062 with Fulvestrant, Pembrolizumab, Sacituzumab Govitecan, Dapagliflozin 10Mg Tab, SM-88, VS-6766, Abemaciclib , and others.
Stay informed about the cutting-edge advancements in HR+ HER2-ve Breast Cancer treatments. Download for updates and be a part of the revolution in care @ HR+ HER2-ve Breast Cancer Clinical Trials Assessment [https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
HR+ HER2-ve Breast Cancer Emerging Drugs Profile
* Camizestrant: AstraZeneca
Camizestrant is a potent, next-generation oral SERD and pure ER antagonist, that has demonstrated anti-cancer activity across a range of preclinical models, including those with ER-activating mutations. The asset has been shown to promising anti-tumour profile when administered alone or in combination with palbociclib and thus, the company is running a Phase III trial for the same.
* Dato-DXd: Daiichi Sankyo, Inc.
Datopotamab deruxtecan (Dato-DXd) is an investigational currently in Phase III for HR-positive, HER2- negative breast cancer. It is a TROP2 directed antibody drug conjugate (ADC) designed using Daiichi Sankyo's proprietary DXd ADC technology, datopotamab deruxtecan is one of the three lead ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programs in AstraZeneca's ADC scientific platform. Datopotamab deruxtecan is comprised of a humanized anti-TROP2 IgG1 monoclonal antibody, developed in collaboration with Sapporo Medical University, attached to a number of topoisomerase I inhibitor payloads, an exatecan derivative, via tetrapeptide-based cleavable linkers.
* CX-2009: CytomX Therapeutics
CX-2009 is a Probody drug conjugate that consists of a humanized anti-CD166 monoclonal antibody conjugated to DM4, a potent microtubule inhibitor known to be active against multiple cancer types. It is currently being tested in Phase II trial in Advanced HR-Positive/HER2-Negative Breast Cancer and of Praluzatamab Ravtansine as Monotherapy and in Combination with Pacmilimab (CX-072) in Advanced Triple-Negative Breast Cancer.
* RGT-419B: Regor Therapeutics
RGT-419B is a new generation of CDK inhibitor with an optimized kinase activity spectrum. The clinical development program of RGT-419B is designed to address the unmet medical needs of patients who are refractory or have relapsed after previous treatment, providing new opportunities to improve survival and quality of life for patients with advanced/metastatic breast cancer. It is currently being tested in Phase I trial in in subjects with Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer.
Learn more about HR+ HER2-ve Breast Cancer Drugs opportunities in our groundbreaking HR+ HER2-ve Breast Cancer Research and development projects @ HR+ HER2-ve Breast Cancer Unmet Needs [https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
HR+ HER2-ve Breast Cancer Companies
Regor Therapeutics, Seagen Inc., CytomX Therapeutics, Taizhou EOC Pharma, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Daiichi Sankyo, Inc., Tyme, Inc., Context Therapeutics, Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Simcere Pharmaceutical Co., Kind Pharmaceuticals, Merus N.V., Atossa Therapeutics, Roche and others
HR Positive/ HER2 Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Discover the latest advancements in HR+ HER2-ve Breast Cancer treatment by visiting our website. Stay informed about how we're transforming the future of disease @ HR+ HER2-ve Breast Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the HR+ HER2-ve Breast Cancer Pipeline Report
* Coverage- Global
* HR+ HER2-ve Breast Cancer Companies- Regor Therapeutics, Seagen Inc., CytomX Therapeutics, Taizhou EOC Pharma, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Daiichi Sankyo, Inc., Tyme, Inc., Context Therapeutics, Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Simcere Pharmaceutical Co., Kind Pharmaceuticals, Merus N.V., Atossa Therapeutics, Roche and others.
* HR+ HER2-ve Breast Cancer Therapies- TQB3616 capsule, NTQ1062 with Fulvestrant, Pembrolizumab, Sacituzumab Govitecan, Dapagliflozin 10Mg Tab, SM-88, VS-6766, Abemaciclib, and others.
* HR+ HER2-ve Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* HR+ HER2-ve Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of HR+ HER2-ve Breast Cancer Pipeline on our website @ HR+ HER2-ve Breast Cancer Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* HR Positive/ HER2 Negative Breast Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* HR Positive/ HER2 Negative Breast Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Dato-DXd: Daiichi Sankyo, Inc.
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* CX-2009: CytomX Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* RGT-419B: Regor Therapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* HR Positive/ HER2 Negative Breast Cancer- Unmet Needs
* HR Positive/ HER2 Negative Breast Cancer- Market Drivers and Barriers
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hr-her2ve-breast-cancer-pipeline-therapeutics-assessment-companies-products-unmet-needs-market-drivers-and-barriers]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release HR+ HER2-ve Breast Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers here
News-ID: 3718825 • Views: …
More Releases from ABNewswire
Rhino Rescue's Quality Pledge: Unveiling the Extreme Resilience of Core Componen …
Discover Rhino Rescue's quality pledge through our extreme component testing. See why our tactical gear is built to perform.
Our Commitment and Responsibility
In the life and death arena of emergency response, where seconds matter, the dependability of your equipment is absolute. It is a fact that has been guiding our mission since our parent company, Nanchi Medical, was established in 2010. Having a 14-year history in the first aid industry and…
Tampa SEO Launches Cutting-Edge Local Search Optimization Services to Help Tampa …
Tampa SEO, a full-service digital marketing agency based in Tampa Bay, today announced the official launch of its enhanced SEO and digital marketing services at http://tampa-seo.net. The company specializes in helping local businesses increase their online visibility, generate qualified leads, and outperform competitors through data-driven, ethical search engine optimization strategies.
Helping Local Businesses Thrive in the Digital Age
With nearly 97% of consumers searching online for local services before making a purchase,…
Fibromyalgia Market Expected to Gain Momentum Through 2034, According to DelveIn …
The Key Fibromyalgia Companies in the market include - Tonix Pharmaceutical, UCB Biopharma SRL, GlaxoSmithKline, UCB Pharma, Pierre Fabre Medicament, UCB Pharma, Eli Lilly and Company, Merck, Aptinyx, Astellas Pharma, AstraZeneca, RiboCor, Inc., Bial - Portela C S.A, and others.
DelveInsight's "Fibromyalgia Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Fibromyalgia, historical and forecasted epidemiology as well as the Fibromyalgia market trends in the United States,…
DMB Plumbing & Heating Urges Homeowners to Schedule Pre-Winter Heating Inspectio …
DMB Plumbing & Heating Inc. of Bridgewater, led by Dean Blanchard, is urging homeowners to schedule pre-winter heating inspections.
As temperatures in Massachusetts begin to dip and residents prepare their homes for another New England winter, DMB Plumbing & Heating Inc., a locally owned and operated company based in Bridgewater, is reminding homeowners of the importance of pre-winter heating inspections.
Founded and operated by Dean Blanchard, DMB Plumbing & Heating has long…
More Releases for HER2
Evolving Market Trends In The HER2-Positive Breast Cancer Industry: Innovative T …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Expected HER2-Positive Breast Cancer Market Size During the Forecast Period?
Over the past few years, there has been a noteworthy expansion in the HER2-positive breast cancer market. The market, which is projected to increase from $10.21 billion in 2024 to $10.96 billion in the following year, predicts a compound annual growth…
HER2 Inhibitors: Advancing Breast Cancer Treatments
"The Business Research Company recently released a comprehensive report on the Global HER2 Inhibitors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
HER2 Positive Breast Cancer Pipeline Drugs 2024
DelveInsight's, "HER2 Positive Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
HER2 Inhibitors: Targeted Therapies Transforming Cancer Treatment
HER2 inhibitors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 9% in the above mentioned forecast period.
Global HER2 Inhibitors Market Scope and Market Size
The HER2 inhibitors market is segmented on the basis of treatment, application, end-users and distribution channel. The growth amongst these segments will help you analyze…
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis.
Although more drug…
HER2 negative Breast Cancer Pipeline involves 85+ key companies continuously wor …
DelveInsight's HER2 negative Breast Cancer Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the HER2 negative Breast Cancer pipeline domain.
Some of the essential takeaways from the HER2 negative Breast Cancer Pipeline report:
• DelveInsight's HER2 negative Breast Cancer Pipeline analysis depicts a robust space with…
